Paper Review — Verify Claims Fast

3.1 Elimination: innate alertness + IFN-γ amplification → adaptive priming

• Elimination is framed as an extrinsic tumor suppressor effect requiring both innate and adaptive immune arms, with an IFN-γ-driven cascade as a common outcome. Elimination cascade with IFN-γ and antigen priming
• The review emphasizes tumor-cell IFN-γ responsiveness as a physiologically relevant target for rejection (e.g., IFN-γ insensitivity can reduce rejection). Tumor-cell IFN-γ responsiveness matters

3.2 Equilibrium: Darwinian selection under persistent immune pressure

• Equilibrium is portrayed as long-term immune containment of genetically unstable tumor clones, where new escape variants arise while selection pressure from lymphocytes/IFN-γ contains the population. Equilibrium as selection under control
• The review links equilibrium duration in humans to long intervals between carcinogen exposure and clinical detection (one cited estimate: ~20 years for many solid tumors). Equilibrium duration estimate

3.3 Escape: immunogenicity loss + effector evasion

• Escape requires circumventing either or both adaptive and innate compartments; the review emphasizes multiple immunoevasive strategies and tumor-cell changes affecting recognition or elimination. Escape as multi-strategy evasion
• Mechanistically, the review highlights reduced antigen presentation (e.g., HLA class I losses and antigen-processing pathway deficiencies) and IFN-γ insensitivity as tumor-level escape mechanisms, citing broad fractions of tumors showing HLA class I allelic losses. Antigen presentation loss and IFN-γ insensitivity as escape

4.1 What the review does well

• Experimental leverage: The review points to genetically defined murine immunodeficiency models (e.g., RAG-1/2, IFN-γ/STAT1, perforin) that enable causal inference about immune components in tumor susceptibility. Causal inference via molecularly defined models
• Conceptual integration: It attempts to connect elimination, equilibrium, and escape with specific immune and tumor-cell mechanisms (IFN-γ cascade, antigen presentation regulation, and IFN-γ responsiveness). Mechanism linkage across phases

4.2 Major blind spots / potential overreach

• Model-to-human mapping: Many key mechanistic claims are grounded in murine carcinogenesis/transplant paradigms; while the review adds human correlative evidence, it does not (within the excerpt provided) fully establish that every tumor type follows the same phase timing or dominant molecular route. Murine-mechanism vs human translation
• Quantification granularity: The review’s human claims are often probabilistic or correlational (e.g., tumor antigenicity changes, TILs associated with survival). Such correlations can be affected by tumor stage, sampling variability, and confounders; the review’s framework implies causality but does not always isolate it at single-cell/spatial resolution in the provided text. Human evidence includes correlative TIL survival associations
• Phase boundaries as conceptual constructs: The three Es are treated as distinct phases, but real tumors may show overlapping dynamics; without quantitative time-resolved data, “phase” labeling can risk post-hoc interpretation. Sculpting continuity may blur sharp phase separations

• If immune activity (or IFN-γ responsiveness) did not measurably constrain tumor initiation in immunodeficiency comparisons, elimination-like tumor suppression would be weaker. Elimination support depends on immune component constraints
• If tumors did not show signs of immune sculpting—i.e., if tumors generated in immunocompetent hosts were not less immunogenic than those generated without intact immunity—equilibrium/escape logic would be undermined. Immunodeficient-origin tumors are more immunogenic on transplant
• If escape variants did not display molecular hallmarks consistent with evasion (e.g., impaired antigen presentation or IFN-γ pathway dysfunction) then the escape mechanism would need revision. Escape mechanism: antigen presentation loss and IFN-γ pathway changes